How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adv-tk.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

AdV-tk — Competitive Intelligence Brief

AdV-tk (AdV-tk) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oncolytic virus. Area: Oncology.

phase 3 Oncolytic virus Tumor cells (HSV-tk prodrug activation pathway) Oncology Biologic Live · refreshed every 30 min

Target snapshot

AdV-tk (AdV-tk) — Candel Therapeutics, Inc.. AdV-tk is an oncolytic adenovirus expressing herpes simplex virus thymidine kinase that replicates in tumor cells and sensitizes them to ganciclovir, triggering both direct viral lysis and immune activation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AdV-tk TARGET	AdV-tk	Candel Therapeutics, Inc.	phase 3	Oncolytic virus	Tumor cells (HSV-tk prodrug activation pathway)
rAd-p53 gene	rAd-p53 gene	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy; oncolytic virus	p53 tumor suppressor gene
Virulizin®	Virulizin®	Aptose Biosciences Inc.	phase 3	Oncolytic virus
rAd-IFN	rAd-IFN	Ferring Ventures Limited	phase 3	oncolytic virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oncolytic virus class)

Aptose Biosciences Inc. · 1 drug in this class
Candel Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AdV-tk — Competitive Intelligence Brief. https://druglandscape.com/ci/adv-tk. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab